For the quarter ending 2025-09-30, XFOR had $30,413K increase in cash & cash equivalents over the period. -$27,822K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -29,815 | -25,459 |
| Stock-based compensation expense | 760 | 1,267 |
| Depreciation and amortization expense | 223 | 831 |
| Gain on sale of non-financial asset | 0 | 0 |
| Non-cash lease expense | 871 | 1,419 |
| Accretion of debt discount | 221 | 437 |
| Change in fair value of warrant liability | 676 | -13,472 |
| Other | 152 | -196 |
| Accounts receivable | -254 | 75 |
| Inventory | 910 | 353 |
| Prepaid expenses, other current and non-current assets and research and development incentive receivable | -421 | -441 |
| Accounts payable | -2,654 | -967 |
| Accrued expenses and other long-term liabilities | 3,365 | -7,555 |
| Deferred revenue | -200 | 1,581 |
| Lease liabilities | -882 | -560 |
| Net cash used in operating activities | -27,822 | -42,269 |
| Acquisition of intangible asset | 0 | 3,000 |
| Proceeds from sale of non-financial asset | 0 | 0 |
| Purchase of marketable securities | 44,534 | 16,953 |
| Sales and maturities of marketable securities | 15,865 | 39,927 |
| Acquisition of property and equipment | 0 | 0 |
| Net cash (used in) provided by investing activities | -28,669 | 19,974 |
| Proceeds from issuance of shares of common stock under employee stock purchase plan | 0 | 46 |
| Proceed from borrowings under loan and security agreement | 0 | 0 |
| Proceeds from sale of shares of common stock, less issuance costs | 86,905 | 5,585 |
| Net cash provided by financing activities | 86,905 | 5,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -1 | 211 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 30,413 | -16,453 |
| Cash and cash equivalents at beginning of period | 56,475 | - |
| Cash and cash equivalents at end of period | 70,435 | - |
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)